The largest published series of valve-in-valve with Core Valve, (Medtronic).

Original title: Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients with Failing Bioprosthetic Aortic Valves. Reference: Axel Linke el al. Circ Cardiovasc Interv. 2012;5:689-697.

This study evaluates the safety, feasibility and results of Core Valve implants on patients with bioprostheses dysfunctional by stenosis, insufficiency or a combination of both.

Biological prostheses are preferred over mechanical ones for patients older than 65 years since no anticoagulation requirements are needed. The problem is that they can deteriorate and eventually lose their function over time. These patients have a high morbidity and mortality rate if they are re-operated. .

27 consecutive patients were treated, symptomatically discarded because of high-risk surgery, (EuroSCORE log 31.3 ± 16.5). Femoral access was under local anesthesia. The events and results of the procedure were analyzed according to the definitions of the Valvular Academic Research Consortium (VARC).

A Core Valve was implanted successfully in all patients. One suffered an embolization but was corrected with a second valve while two died after procedure.

Gradients decreased by 83%, (peak gradient of 58 ± 21 to 12 ± 8 mmHg and mid gradient of 42 ± 15 to 10 ± 8 mmHg). 3 patients stayed on grade 2 aortic regurgitation diagnosis. According to VARC definitions, success was not achieved in 11 of the 27 patients, (44%). All symptoms improved, even those in which the mid-gradient remained > 20 mmHg. 30-day mortality was 7.4% and at long follow-up, (421 ± 198 days), it was 15%. One patient, (2.7%), required a permanent pacemaker.

Conclusions: 

The implantation of a Core Valve, (Medtronic), for femoral access under local anesthesia for patients with dysfunctional bioprostheses is safe and feasible in this high-risk cohort.

Editorial comment:

Although more than 15,000 Core Valve, (Medtronic), have been implanted worldwide, experience in treating dysfunctional bioprostheses is limited. This is the largest series of valve-in-valve Valve Core followed for more than one year. It is noteworthy that the gradient post implant, although significantly improved compared to baseline, was below the outcome in patients with native valve. This could be due to a mismatch between the patient and the original prosthesis. It also draws attention to the low need for a permanent pacemaker post implantation, (only 2.7%). It is possible that fibrosis due to previous surgery somehow protects the drive system. Patients with a dysfunctional biological valve can be treated with the Core Valve implantation with good long-term results and a clear clinical improvement, although we should be less demanding regarding residual gradients

 

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...